RxDoctor Payments Data

Kartik Shatagopam, MD

Interventional Cardiology · Salisbury, NCNPI 1083905061

Payments from drug & device makers

$1,754in general payments, 2019–2025

Across 37 payments — averaging $47.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$786
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$165
  • Abiomed$162
  • E.r. Squibb & Sons, L.L.C.$143
  • Teleflex LLC$130
  • Medtronic$118
  • plus $250 from 6 others

What the payments were for

  • Food & beverage$1,754100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,754 in reported general payments places this provider in the 15th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$128,814
Medicare patients
588
Services billed
1,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban302$222,135
EntrestoSacubitril/Valsartan101$82,709
Repatha SureclickEvolocumab62$42,699
JardianceEmpagliflozin48$37,107
BrilintaTicagrelor67$33,741
XareltoRivaroxaban29$26,845
Praluent PenAlirocumab35$21,270
FarxigaDapagliflozin Propanediol28$17,023
Ranolazine ErRanolazine65$5,277
Prasugrel Hcl67$4,378
Carvedilol433$2,616
Rosuvastatin Calcium239$2,065
Torsemide113$1,740
Metoprolol Succinate247$1,527
Metoprolol Tartrate279$1,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$56$82,709101 claims
AstraZenecaBrilinta, Farxiga$44$50,76495 claims
Johnson & JohnsonXarelto$12$26,84529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Salisbury

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →